☆ 4.7 Editorial Material

Chemotherapy for advanced urothelial cancer: end of the beginning?

LANCET ONCOLOGY (2017)

Get Full Text
Add to Collection

Journal

LANCET ONCOLOGY
Volume 18, Issue 5, Pages 567-569

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(17)30241-3

Keywords

-

Categories

Oncology

Funding

  1. Genentech
  2. Asana
  3. Astellas
  4. Astra Zeneca
  5. Bristol-Myers Squibb
  6. Churchill Pharma
  7. Eisai
  8. Exelixis
  9. Medivation
  10. Orion
  11. Sanofi-Genzyme

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.